1. < Home

Therapeutics

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad[...]

By sjmartinez • April 14, 2024
STRONG-HF and Implementing Heart Failure Therapies: Godspeed … With Care

Butler J, Talha KM, Fonarow GC. STRONG-HF and Implementing Heart Failure Therapies: Godspeed … With Care. Circulation. 2023 Apr 18;147(16):1189-1191. doi: 10.1161/CIRCULATIONAHA.122.063811. Epub 2023 Apr[...]

By sjmartinez • April 19, 2023
Mechanistic insight into the protective and pathogenic immune

Purbey PK, Roy K, Gupta S, Paul MK. Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. Mol Immunol. 2023 Mar 10;156:111-126. doi: 10.1016/j.molimm.2023.03.009.[...]

By sjmartinez • March 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, Kuwana M, Stock C, Alves M, Sambevski S, Denton[...]

By sjmartinez • February 17, 2023
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas[...]

By sjmartinez • September 22, 2022